Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments.
The venture between Washington D.C.-based Danaher, a science and technology company, and U.K. drugmaker AstraZeneca will utilize the new Danaher Centers for Enabling Precision Medicine.
"We are excited to work with AstraZeneca on the goal of creating novel tests to increase access to precision medicines, helping ensure that no patients are left behind," Danaher Executive Vice President Julie Sawyer Montgomery said Thursday.
The first product to be developed will use technologies from Leica Biosystems, a Danaher subsidiary. The initial focus will be on developing artificial intelligence-powered diagnostics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.